Analysts expect Neogenomics Inc to report revenue of 777.63 M for 2026, against a range of 710.20 M to 845.06 M. The most recent reported year, 2025, came in at 727.33 M, a 6.1% beat against the 685.32 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 484.33 M | 509.73 M | 591.64 M | 660.57 M | 727.33 M | - | - | ||
| High Estimate | 523.88 M | 521.69 M | 649.75 M | 754.56 M | 744.49 M | 845.06 M | 864.37 M | ||
| Low Estimate | 475.08 M | 447.52 M | 552.02 M | 651.91 M | 626.15 M | 710.20 M | 793.37 M | ||
| Consensus Estimate | 499.48 M | 484.61 M | 600.88 M | 703.23 M | 685.32 M | 777.63 M | 828.87 M |
Analysts expect Neogenomics Inc to report earnings per share of 0.19 for 2026, against a range of 0.18 to 0.20. The most recent reported year, 2025, came in at 0.12, a 33.3% beat against the 0.09 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.27 | -0.56 | -0.12 | 0.11 | 0.12 | - | - | ||
| High Estimate | -0.25 | -0.60 | -0.15 | 0.11 | 0.10 | 0.20 | 0.38 | ||
| Low Estimate | -0.27 | -0.70 | -0.17 | 0.09 | 0.08 | 0.18 | 0.34 | ||
| Consensus Estimate | -0.26 | -0.65 | -0.16 | 0.10 | 0.09 | 0.19 | 0.36 |
Pull Wall Street consensus for Neogenomics Inc (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NEO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NEO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NEO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();